Black Diamond Therapeutics (BDTX) Stock Price, News & Analysis

Company Overview

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $2.15 to $2.31
• 50-Day Range: $1.36 to $2.58
• 52-Week Range: $1.20 to $6.75
• Volume: 907,939 shs
• Average Volume: 1.54 million shs
• Market Capitalization: $129.08 million
• P/E Ratio: 37.83
• Dividend Yield: N/A
• Price Target: $14.60
• Consensus Rating: Buy

Black Diamond Therapeutics Stock Analysis - MarketRank™

Black Diamond Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 359th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Black Diamond Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Black Diamond Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Black Diamond Therapeutics are expected to grow in the coming year, from ($1.30) to ($1.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Black Diamond Therapeutics is 37.83, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.76.

Price to Earnings Ratio vs. Sector

The P/E ratio of Black Diamond Therapeutics is 37.83, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.75.

Price to Book Value per Share Ratio

Black Diamond Therapeutics has a P/B Ratio of 1.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

14.68% of the float of Black Diamond Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Black Diamond Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Black Diamond Therapeutics has recently decreased by 6.31%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Black Diamond Therapeutics does not currently pay a dividend.

Dividend Growth

Black Diamond Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

14.68% of the float of Black Diamond Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Black Diamond Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Black Diamond Therapeutics has recently decreased by 6.31%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

Black Diamond Therapeutics has a news sentiment score of 1.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.

Search Interest

Only 5 people have searched for BDTX on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

MarketBeat Follows

13 people have added Black Diamond Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 550% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Black Diamond Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.97% of the stock of Black Diamond Therapeutics is held by insiders.

Percentage Held by Institutions

95.47% of the stock of Black Diamond Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BDTX Stock Analysis - Frequently Asked Questions

How have BDTX shares performed this year?

Black Diamond Therapeutics' stock was trading at $2.14 on January 1st, 2025. Since then, BDTX stock has increased by 6.1% and is now trading at $2.27.
View the best growth stocks for 2025 here.

How were Black Diamond Therapeutics' earnings last quarter?

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) released its earnings results on Thursday, March, 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.03.

When did Black Diamond Therapeutics IPO?

Black Diamond Therapeutics (BDTX) raised $151 million in an initial public offering (IPO) on Thursday, January 30th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Who are Black Diamond Therapeutics' major shareholders?

Black Diamond Therapeutics' top institutional investors include T. Rowe Price Investment Management Inc. (18.35%), AWM Investment Company Inc. (0.88%), Affinity Asset Advisors LLC (0.44%) and Brown Wealth Management LLC (0.18%). Insiders that own company stock include Ali Behbahani, Growth N V Biotech, David M Epstein and Fang Ni.
View institutional ownership trends.

How do I buy shares of Black Diamond Therapeutics?

Shares of BDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Black Diamond Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Black Diamond Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), Ginkgo Bioworks (DNA), COMPASS Pathways (CMPS), Toast (TOST), Meta Platforms (META) and Luminar Technologies (LAZR).

Company Calendar

• Last Earnings: 3/06/2025
• Today: 6/23/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BDTX
• CIK: 1701541
• Web: N/A
• Phone: 617-252-0848
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $14.60
• High Stock Price Target: $20.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +538.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.06
• Trailing P/E Ratio: 38.02
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$69.68 million
• Net Margins: N/A
• Pretax Margin: 7.27%
• Return on Equity: 4.70%
• Return on Assets: 3.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.24
• Quick Ratio: 9.24

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.47 per share
• Price / Book: 1.55

Miscellaneous

• Outstanding Shares: 56,860,000
• Free Float: 53,468,000
• Market Cap: $129.93 million
• Optionable: Optionable
• Beta: 2.71